TWI552762B - 雙組分口腔保健產品 - Google Patents
雙組分口腔保健產品 Download PDFInfo
- Publication number
- TWI552762B TWI552762B TW103121297A TW103121297A TWI552762B TW I552762 B TWI552762 B TW I552762B TW 103121297 A TW103121297 A TW 103121297A TW 103121297 A TW103121297 A TW 103121297A TW I552762 B TWI552762 B TW I552762B
- Authority
- TW
- Taiwan
- Prior art keywords
- component
- weight
- phosphate
- calcium
- fluoride
- Prior art date
Links
- 230000009977 dual effect Effects 0.000 title description 4
- 239000000203 mixture Substances 0.000 claims description 55
- 150000001413 amino acids Chemical class 0.000 claims description 22
- 239000004475 Arginine Substances 0.000 claims description 21
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 20
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 19
- 239000011575 calcium Substances 0.000 claims description 13
- 229910052791 calcium Inorganic materials 0.000 claims description 13
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 12
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 11
- 206010020751 Hypersensitivity Diseases 0.000 claims description 8
- 150000001450 anions Chemical class 0.000 claims description 7
- 208000026935 allergic disease Diseases 0.000 claims description 6
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 5
- 229910019142 PO4 Inorganic materials 0.000 claims description 5
- 229910001424 calcium ion Inorganic materials 0.000 claims description 5
- 230000009610 hypersensitivity Effects 0.000 claims description 5
- 239000010452 phosphate Substances 0.000 claims description 5
- 229940085991 phosphate ion Drugs 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 3
- 229910004261 CaF 2 Inorganic materials 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- GUYBGCBOZOALMT-UHFFFAOYSA-J dicalcium;fluoride;phosphate Chemical compound [F-].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O GUYBGCBOZOALMT-UHFFFAOYSA-J 0.000 claims 1
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 1
- 239000001488 sodium phosphate Substances 0.000 claims 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical group [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 1
- 239000000551 dentifrice Substances 0.000 description 39
- 235000001014 amino acid Nutrition 0.000 description 21
- 235000009697 arginine Nutrition 0.000 description 17
- 229940091249 fluoride supplement Drugs 0.000 description 15
- 239000000606 toothpaste Substances 0.000 description 12
- -1 fluoride ions Chemical class 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 229940034610 toothpaste Drugs 0.000 description 11
- 239000003242 anti bacterial agent Substances 0.000 description 10
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 10
- 239000002562 thickening agent Substances 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000036541 health Effects 0.000 description 9
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 210000003298 dental enamel Anatomy 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000002324 mouth wash Substances 0.000 description 8
- 229940051866 mouthwash Drugs 0.000 description 8
- 229960003500 triclosan Drugs 0.000 description 8
- 210000005239 tubule Anatomy 0.000 description 8
- 208000002925 dental caries Diseases 0.000 description 7
- 210000004268 dentin Anatomy 0.000 description 7
- 239000000975 dye Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000000049 pigment Substances 0.000 description 7
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 6
- 230000000675 anti-caries Effects 0.000 description 6
- 229910052700 potassium Inorganic materials 0.000 description 6
- 239000011591 potassium Substances 0.000 description 6
- 229960003975 potassium Drugs 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 5
- 230000036996 cardiovascular health Effects 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 210000000214 mouth Anatomy 0.000 description 5
- 230000007935 neutral effect Effects 0.000 description 5
- 239000004323 potassium nitrate Substances 0.000 description 5
- 235000010333 potassium nitrate Nutrition 0.000 description 5
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 5
- 239000003765 sweetening agent Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000001680 brushing effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 238000005115 demineralization Methods 0.000 description 4
- 230000002328 demineralizing effect Effects 0.000 description 4
- 201000002170 dentin sensitivity Diseases 0.000 description 4
- 239000003906 humectant Substances 0.000 description 4
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- RYJDNPSQBGFFSF-WCCKRBBISA-N (2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;carbonic acid Chemical compound OC(O)=O.OC(=O)[C@@H](N)CCCNC(N)=N RYJDNPSQBGFFSF-WCCKRBBISA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000003082 abrasive agent Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 125000000129 anionic group Chemical group 0.000 description 3
- 230000003139 buffering effect Effects 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 229910000420 cerium oxide Inorganic materials 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 235000011180 diphosphates Nutrition 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- BMMGVYCKOGBVEV-UHFFFAOYSA-N oxo(oxoceriooxy)cerium Chemical compound [Ce]=O.O=[Ce]=O BMMGVYCKOGBVEV-UHFFFAOYSA-N 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 235000019832 sodium triphosphate Nutrition 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 208000006558 Dental Calculus Diseases 0.000 description 2
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920000388 Polyphosphate Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 206010000059 abdominal discomfort Diseases 0.000 description 2
- 150000001339 alkali metal compounds Chemical class 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 230000003113 alkalizing effect Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000004075 cariostatic agent Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000013477 citrulline Nutrition 0.000 description 2
- 229960002173 citrulline Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 2
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 2
- 229940038472 dicalcium phosphate Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 150000002222 fluorine compounds Chemical class 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- UPBDXRPQPOWRKR-UHFFFAOYSA-N furan-2,5-dione;methoxyethene Chemical compound COC=C.O=C1OC(=O)C=C1 UPBDXRPQPOWRKR-UHFFFAOYSA-N 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 2
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000001205 polyphosphate Substances 0.000 description 2
- 235000011176 polyphosphates Nutrition 0.000 description 2
- 229910001414 potassium ion Inorganic materials 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000011775 sodium fluoride Substances 0.000 description 2
- 235000013024 sodium fluoride Nutrition 0.000 description 2
- 229960000414 sodium fluoride Drugs 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 2
- JLPAMKUIIFHLBH-UHFFFAOYSA-N 1,2-dihydroxypropane-1-sulfonic acid Chemical compound CC(O)C(O)S(O)(=O)=O JLPAMKUIIFHLBH-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- BLCJBICVQSYOIF-UHFFFAOYSA-N 2,2-diaminobutanoic acid Chemical compound CCC(N)(N)C(O)=O BLCJBICVQSYOIF-UHFFFAOYSA-N 0.000 description 1
- RPZANUYHRMRTTE-UHFFFAOYSA-N 2,3,4-trimethoxy-6-(methoxymethyl)-5-[3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxyoxane;1-[[3,4,5-tris(2-hydroxybutoxy)-6-[4,5,6-tris(2-hydroxybutoxy)-2-(2-hydroxybutoxymethyl)oxan-3-yl]oxyoxan-2-yl]methoxy]butan-2-ol Chemical compound COC1C(OC)C(OC)C(COC)OC1OC1C(OC)C(OC)C(OC)OC1COC.CCC(O)COC1C(OCC(O)CC)C(OCC(O)CC)C(COCC(O)CC)OC1OC1C(OCC(O)CC)C(OCC(O)CC)C(OCC(O)CC)OC1COCC(O)CC RPZANUYHRMRTTE-UHFFFAOYSA-N 0.000 description 1
- UBLAMKHIFZBBSS-UHFFFAOYSA-N 3-Methylbutyl pentanoate Chemical compound CCCCC(=O)OCCC(C)C UBLAMKHIFZBBSS-UHFFFAOYSA-N 0.000 description 1
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 1
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 1
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 1
- ZUGAOYSWHHGDJY-UHFFFAOYSA-K 5-hydroxy-2,8,9-trioxa-1-aluminabicyclo[3.3.2]decane-3,7,10-trione Chemical compound [Al+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ZUGAOYSWHHGDJY-UHFFFAOYSA-K 0.000 description 1
- XFJKNSKUUNJAIV-UHFFFAOYSA-N 5-oxo-4-phenyl-1,2-dihydropyrazole-3-carboxylic acid Chemical compound N1NC(=O)C(C=2C=CC=CC=2)=C1C(=O)O XFJKNSKUUNJAIV-UHFFFAOYSA-N 0.000 description 1
- RFRMMZAKBNXNHE-UHFFFAOYSA-N 6-[4,6-dihydroxy-5-(2-hydroxyethoxy)-2-(hydroxymethyl)oxan-3-yl]oxy-2-(hydroxymethyl)-5-(2-hydroxypropoxy)oxane-3,4-diol Chemical compound CC(O)COC1C(O)C(O)C(CO)OC1OC1C(O)C(OCCO)C(O)OC1CO RFRMMZAKBNXNHE-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- 229940090898 Desensitizer Drugs 0.000 description 1
- RZSYLLSAWYUBPE-UHFFFAOYSA-L Fast green FCF Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC(O)=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 RZSYLLSAWYUBPE-UHFFFAOYSA-L 0.000 description 1
- XKTMIJODWOEBKO-UHFFFAOYSA-M Guinee green B Chemical compound [Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC=CC=2)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 XKTMIJODWOEBKO-UHFFFAOYSA-M 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 235000011203 Origanum Nutrition 0.000 description 1
- 240000000783 Origanum majorana Species 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 208000036372 Sensitivity of teeth Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010044038 Tooth erosion Diseases 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002053 acidogenic effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002553 antibacterial enhancer Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- IRERQBUNZFJFGC-UHFFFAOYSA-L azure blue Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[S-]S[S-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] IRERQBUNZFJFGC-UHFFFAOYSA-L 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical class C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 1
- 235000012745 brilliant blue FCF Nutrition 0.000 description 1
- 239000004161 brilliant blue FCF Substances 0.000 description 1
- 150000003842 bromide salts Chemical class 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical compound [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- 229910001634 calcium fluoride Inorganic materials 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 229940043256 calcium pyrophosphate Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000001013 cariogenic effect Effects 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 1
- 229910000423 chromium oxide Inorganic materials 0.000 description 1
- 239000010630 cinnamon oil Substances 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 201000009241 dentin caries Diseases 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical class C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- IRXRGVFLQOSHOH-UHFFFAOYSA-L dipotassium;oxalate Chemical compound [K+].[K+].[O-]C(=O)C([O-])=O IRXRGVFLQOSHOH-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 1
- 235000012732 erythrosine Nutrition 0.000 description 1
- 239000004174 erythrosine Substances 0.000 description 1
- 229940011411 erythrosine Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 235000019240 fast green FCF Nutrition 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229940051147 fd&c yellow no. 6 Drugs 0.000 description 1
- 238000002666 fluoride therapy Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000000576 food coloring agent Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 201000005562 gingival recession Diseases 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- HNMCSUXJLGGQFO-UHFFFAOYSA-N hexaaluminum;hexasodium;tetrathietane;hexasilicate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].S1SSS1.S1SSS1.[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] HNMCSUXJLGGQFO-UHFFFAOYSA-N 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- KHLVKKOJDHCJMG-QDBORUFSSA-L indigo carmine Chemical compound [Na+].[Na+].N/1C2=CC=C(S([O-])(=O)=O)C=C2C(=O)C\1=C1/NC2=CC=C(S(=O)(=O)[O-])C=C2C1=O KHLVKKOJDHCJMG-QDBORUFSSA-L 0.000 description 1
- 235000012738 indigotine Nutrition 0.000 description 1
- 239000004179 indigotine Substances 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910000400 magnesium phosphate tribasic Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000013588 oral product Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- RARSHUDCJQSEFJ-UHFFFAOYSA-N p-Hydroxypropiophenone Chemical compound CCC(=O)C1=CC=C(O)C=C1 RARSHUDCJQSEFJ-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- XCOJIVIDDFTHGB-YRNVUSSQSA-N perilla sugar Chemical compound CC(=C)C1CCC(\C=N\O)=CC1 XCOJIVIDDFTHGB-YRNVUSSQSA-N 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920005646 polycarboxylate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 229940094025 potassium bicarbonate Drugs 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229960002816 potassium chloride Drugs 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- OQZCJRJRGMMSGK-UHFFFAOYSA-M potassium metaphosphate Chemical compound [K+].[O-]P(=O)=O OQZCJRJRGMMSGK-UHFFFAOYSA-M 0.000 description 1
- 229940099402 potassium metaphosphate Drugs 0.000 description 1
- 229940093928 potassium nitrate Drugs 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000010670 sage oil Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000010672 sassafras oil Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 1
- 235000019983 sodium metaphosphate Nutrition 0.000 description 1
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- FIWQZURFGYXCEO-UHFFFAOYSA-M sodium;decanoate Chemical compound [Na+].CCCCCCCCCC([O-])=O FIWQZURFGYXCEO-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- ANOBYBYXJXCGBS-UHFFFAOYSA-L stannous fluoride Chemical compound F[Sn]F ANOBYBYXJXCGBS-UHFFFAOYSA-L 0.000 description 1
- 229960002799 stannous fluoride Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- AGGIJOLULBJGTQ-UHFFFAOYSA-N sulfoacetic acid Chemical compound OC(=O)CS(O)(=O)=O AGGIJOLULBJGTQ-UHFFFAOYSA-N 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-I triphosphate(5-) Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O UNXRWKVEANCORM-UHFFFAOYSA-I 0.000 description 1
- 235000013799 ultramarine blue Nutrition 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 239000010455 vermiculite Substances 0.000 description 1
- 229910052902 vermiculite Inorganic materials 0.000 description 1
- 235000019354 vermiculite Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/20—Halogens; Compounds thereof
- A61K8/21—Fluorides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/88—Two- or multipart kits
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
Description
此專利申請案主張2008年2月8日提出之美國專利申請案號61/027,422的利益,藉由引述將其內容併入於此。
本發明係關於雙組分潔齒劑配製物,其中配製物內的反應組分在使用前彼此螯合。在一具體實施例中,本發明係關於一種可消除或減少牙齒過敏相關之不適和疼痛的去敏化潔齒劑組成物,以及更明確而言係關於含有游離或鹽基鹼性胺基酸以及鈣離子組分和一陰離子組分而具有意外加強抗齲齒和再礦化性質的去敏牙齒組成物。
牙齒過敏被定義為反應牙本質表面對溫度(熱或冷)、滲透壓、觸覺之牙質物理性刺激結合暴露牙質之溫度、滲透壓和觸覺刺激的急性、局部牙齒疼痛。
一般導因於牙齦退縮或失去琺瑯質的牙本質暴露經常造成過敏。已知牙質敏感與牙本質小管開口至表面具有極大的關聯性,Abs,J.Clin.Periodontal.14:280~4(1987)。牙本質小管係從牙髓連通至牙骨質。當齒根的牙骨質表面被腐蝕時,牙本質小管將暴露於外部環境。暴露牙本質小管將產生液體流至牙髓神經的路徑,而傳遞作用將被溫度、壓力和離子梯度的變化所誘發。
技術中已知鉀鹽可有效用於治療牙本質的敏感。例如美國專利案3,863,006中揭示含鉀鹽如硝酸鉀的牙膏在刷牙數週之後可使牙齒去敏
化。熟習本領域的技術者認為提高敏感牙質下牙髓神經附近的細胞外鉀濃度為局部塗抹含硝酸鉀之口腔產品具有治療性去敏化效應的原因。由於鉀離子係被動擴散入和出牙本質小管的開口,因此必需重複塗抹該活性成分以便在齒髓神經附近產生所需的濃度。
已認為利用鉀鹽配合可完全或部分阻塞牙本質小管的牙質表面逐漸礦化可獲得疼痛的緩解。完全阻塞將可戲劇化地減少造成疼痛刺激的液體流入小管內。由於向內擴散通量較向外液流不依賴小管半徑(因正髓壓)因此認為牙本質小管的部分阻塞可增加牙齒內的鉀離子輸送(請看D.H.Pashely和W.G.Mathews,Archs.Oral Biol.(1993)38:577~582)。因此,加強鉀的輸送可增強緩解。
潔齒劑內長久以來已知使用釋氟化合物作為抗齲齒劑,以及已確信這些化合物可有效降低齲齒的發生率。常用的氟化物為氟化鈉、單氟磷酸鈉和氟化亞錫。氟化物的效力主要歸因於氟離子可改善琺瑯質的抗酸性以及加速僅輕微脫礦化之早期齲齒的再鈣化或再礦化。藉由再礦化,可減少或消除先前存在的蛀牙和齲齒而降低先前齒內構造的齲齒狀況。已認為改善琺瑯質抗酸性的效應歸因於氟離子被併入琺瑯質主成分之羥基磷灰石的晶格內或,換言之,氟離子部分加氟羥基磷灰石及同時修補不規則晶格。
氟化物治療的有效性係依賴沈積於被治療琺瑯質上之可用氟離子的數量。因此配製潔齒劑組成物時較佳為使潔齒劑能於刷洗液內產生最大量的氟離子。
精胺酸和其他鹼性胺基酸已被建議用於口腔保健並且證明在對抗齲齒和牙齒過敏性上具有顯著的效益。結合這些鹼性胺基酸與具有口腔保健效益的礦物質例如氟和鈣可形成具有長期可接受穩定性的口腔保
健產品,然而,仍存在許多困難度。明確而言,該鹼性胺基酸可能升高pH值而易於使與氟離子反應以形成不溶性沈澱物的鈣離子產生解離。此外,較高的pH較易造成刺激性。然而,在中性或酸性pH時,利用精胺酸重碳酸鹽的系統(較佳技術)可能釋出二氧化碳而導致容器的膨脹和爆裂。此外,由於精胺酸可形成低齒面親和力的不溶性精胺酸-鈣複合物而預期降低pH至中性或酸性條件將降低其形成效率,以及甚者該pH的降低將減少對口腔內緩衝性生齲乳酸形成的任何效應。部分由於這些未解決的配製物障礙及部分由於精胺酸在技術中被視為氟化物的替代物而非共同作用,因此口腔保健產品內不需同時含有精胺酸和氟化物。其他可能的障礙為添加抗菌劑所造成。市售精胺酸為主的牙膏例如ProClude®和DenClude®含有精胺酸重碳酸鹽和碳酸鈣,但不含氟化物或任何的抗菌劑。
先前揭示技術雖然使用各種口腔組成物於治療牙質過敏、齲齒和琺瑯質脫礦化,但是仍亟需可改善此類治療效果的其他組成物和方法。
根據本發明提供一種用於治療牙質過敏之具有改善抗齲齒和再礦化性質的口腔組成物和方法,該組成物含有鈣離子源組分、陰離子源組分,和含有鹼性胺基酸的至少一種組分,各組分被選擇性地含於一口腔可接受載劑內,該第一和第二組分保持相互分開直至被分散和混合施用於需舒緩的牙質過敏牙齒,因而在重複使用組成物至牙齒之後使用者可感覺到牙質過敏的緩解並且改善抗齲齒效果。
在另一具體實施例中,本發明包括改善口腔健康的方法,其包含將有效量的口腔組成物施予至有需要個體的口腔內,例如係一種方法可:
a. 減少或抑制蛀牙的形成;b. 減少、修補或抑制早期琺瑯質病變,例如藉由定量光激發螢光技術(QLF)或電齲齒測量法(ECM)的測定;c. 減少或抑制牙齒的去礦化及促進再礦化;d. 減少牙齒過敏性;e. 減少或抑制齒齦炎;f. 促進口腔內潰瘍或傷口的癒合;g. 降低產酸菌的濃度;h. 增加精胺酸溶解菌的相對濃度;i. 抑制口腔內微生物生物膜的形成;j. 吃甜食之後上升及/或維持牙垢pH在至少pH 5.5的程度;k. 減少牙垢的積聚;l. 治療口乾症;m. 促進包括心血管健康的身體健康,例如減少經由口腔組織造成全身性感染的可能性;n. 潔白牙齒;o. 減少牙齒的腐蝕;p. 免疫牙齒對抗致齲菌;及/或q. 清潔牙齒和口腔。
“氟離子源”被定義為可溶性氟化物或未共價鍵連接之氟化物的來源。
“陰離子源”被定義為氟離子源、磷酸鹽離子源,或其混合物。
“鈣源”被定義為可輕易地與磷酸鹽離子反應以沈澱成CaPO4或與氟化物反應以產生CaF2之鈣或氟化鈣-磷酸鹽之混合物的鈣來
源。
“磷酸鹽離子源”被定義為非共價鍵之磷酸鹽的來源。
本發明的組成物係一種雙組分組成物,包括在例如約pH 5至約9.9含有鈣離子源的第一潔齒劑組分,以及含有陰離子源的第二潔齒劑組分,例如經緩衝以維持實質上中性pH例如約6.5至約7之具有游離或鹽型鹼性胺基酸而存在於其一或兩者第一和第二潔齒劑組分內。該兩種組分較佳為以約相等重量比例相混合,因而當該組分被混合及施予至牙齒如藉由刷牙時其將具有約任一組分內任何特定成分的一半濃度。兩種組分較佳為被配製成具有類似的物理性能,因而當分置於多室管或泵壓裝置內時該兩種組分可同時被分配成所欲的預設量。
在本發明的雙組分潔齒劑中,製備具有鹼性pH的其一潔齒劑組分以及另外類似於具有緩衝中性pH的組成物。該鹼性組分的pH被調節至約8.5至約9.7的pH以及較佳為約9至約9.5。混合潔齒劑組分的pH係在約7.5至約8.6的範圍內以及較佳為約7.5至約8.5。
鹼化劑例如鹼金屬化合物包括氫氧化鈉、氫氧化鉀、重碳酸鈉、碳酸鈉、N-矽酸鈉(供應自PQ公司之34.6%水中的矽酸鈉)、鹼性胺基酸,或鹼性胺基酸的重碳酸鹽例如精胺酸重碳酸鹽,其被併入雙組分潔齒劑之鹼性pH潔齒劑組分內的量為約0.5至約15%重量比,較佳為約1至約8%重量比及最佳為約1至約5%重量比的該組分。亦可使用上述鹼金屬化合物的混合物。氫氧化鈉為較佳的鹼化劑。可被用於本發明之組成物和方法的鹼性胺基酸不僅包括天然鹼性胺基酸例如精胺酸、離胺酸和組胺酸亦包括分子內具有羥基和胺基的任何鹼性胺基酸,其為水溶性及可提供水溶液約7或更高的pH,例如至少約8。
因此,鹼性胺基酸包括但不侷限於精胺酸、離胺酸、瓜胺酸、
鳥胺酸、肌酸、組胺酸、二胺基丁酸、二胺基丙酸,其鹽及/或其組合。在一特定具體實施例中,該鹼性胺基酸係選自精胺酸、瓜胺酸和鳥胺酸。
在某些具體實施例中,該鹼性胺基酸係精胺酸例如1-精胺酸,或其鹽。
本發明組成物擬供口內局部使用以及用於本發明的鹽類在提供的數量和濃度下必需為安全。適當鹽類包括在提供的數量和濃度之下通常被視為生理上可接受之醫藥上可接受鹽的技術中已知鹽類。生理上可接受鹽包括衍自醫藥上可接受無機或有機酸或鹼者,例如藉由形成生理上可接受陰離子之酸所形成的酸加成鹽例如鹽酸鹽、溴化鹽,以及藉由形成生理上可接受陽離子之鹼所形成的鹼加成鹽例如衍自鹼金屬如鉀和鈉或鹼土金屬如鈣和鎂者。利用技術中已知的標準程序可獲得生理上可接受鹽,例如藉由足量鹼性化合物如胺與可形成生理上可接受陰離子之適當酸的反應。在一些具體實施例中,該鹼性胺基酸在與鈣、氟或其他反應組分配製之前被與酸例如鹽酸、磷酸或碳酸中和而形成鹽或不完全鹽。
在各種具體實施例中,該鹼性胺基酸的含量為約0.5重量%至約20重量%的總組成物重量,約1至約10重量%的總組成物重量,例如約1.5重量%、3.75重量%、5重量%或7.5重量%的總組成物重量。
用於製備本發明潔齒劑組成物之載劑的濕潤劑通常係一種濕潤劑的混合物,例如分子量在約200至約1000範圍內的甘油、山梨糖醇和聚乙二醇,但亦可使用濕潤劑和單一濕潤劑的其他混合物。該濕潤劑的含量範圍為約10%至約50%重量比及較佳為在約20至約40%重量比的潔齒劑組分。水的含量範圍為在約20至約50%重量比及較佳為在約30至約40%重量比。
用於製備潔齒劑載劑的增稠劑包括有機和無機增稠劑。可用
於潔齒劑組分內的無機增稠劑包括非晶形矽例如供應自Huber公司的Zeodent 165以及供應自W.R.Grace公司的Sylox 15。
天然和合成樹膠和膠體的有機增稠劑亦可被用於製備本發明的潔齒劑組分。此類增稠劑的實例為卡拉膠(Irish moss公司)、三仙膠、羧甲基纖維素鈉、澱粉、聚乙烯吡咯啶酮、羥乙基丙基纖維素、羥丁基甲基纖維素、羥丙基甲基纖維素和羥乙基纖維素。
併入本發明潔齒劑組成物內之無機增稠劑的濃度為約0.5至約5%重量比及較佳為約1至約3%重量比。併入本發明組成物內之有機增稠劑的濃度為約0.1至約3%重量比及較佳為約0.4至約1.5%重量比。
潔齒劑組成物內可併入表面活性劑以提供發泡性能。表面活性劑較佳為陰離子或非離子性質。陰離子表面活性劑的適當實例為高級烷基硫酸鹽例如較佳的月桂基硫酸鉀或鈉、高級脂肪酸單甘油單硫酸鹽例如氫化椰油脂肪酸之單硫酸化單甘油的鹽類、烷基芳基硫酸鹽例如十二烷基苯磺酸鈉、高級脂肪磺基乙酸鹽、1,2-二羥基丙磺酸鹽的高級脂肪酸酯。
本發明潔齒劑組成物內的表面活性劑濃度通常為約0.5至約10%重量比及較佳為約1至約5%重量比。
磨料可被併入本發明的潔齒劑組成物內以及較佳的磨料為矽質材料例如氧化矽。較佳氧化矽為沈澱非晶形水合矽石例如Crosfield化學公司販售的Sorbosil AC-35或來自Huber公司的Zeodent 115,但亦可使用其他的磨料包括羥基磷灰石、偏磷酸鈉、偏磷酸鉀、磷酸三鈣、二水磷酸鈣、無水磷酸二鈣、焦磷酸鈣、正磷酸鎂、磷酸三鎂、碳酸鈣、重碳酸鈉、三水氧化鋁、矽酸鋁、燒結氧化鋁和膨潤土。
磨料在本發明潔齒劑組成物內的濃度範圍通常在約5至約40%重量比及較佳為約10至約25%重量比。
去敏鉀離子的來源通常為水溶性鉀鹽包括硝酸鉀、檸檬酸鉀、氯化鉀、重碳酸鉀和草酸鉀,其中以硝酸鉀較佳。被併入一或多種潔齒劑組分內的鉀鹽濃度通常為約1至約20%重量比及較佳為約3至約10%重量比。
活性成分的濃度根據輸送系統和特定活性的性質而異。例如該鹼性胺基酸的濃度為從例如約0.1至約20重量%(以游離鹼重量表示),例如潄口液為約0.1至約3重量%、消費性牙膏為約1至約10重量%或專業或處方治療產品為約7至約20重量%。氟化物的含量為從例如約25至約25,000ppm,例如潄口液為約25至約250ppm,消費性牙膏為約750至約2,000ppm,或專業或處方治療產品為約2,000至約25,000ppm。抗菌劑的濃度變化亦類似,用於牙膏的濃度為大於例如用於潄口液中的約5至約15倍。例如,三氯沙潄口液可含有例如約0.03重量%的三氯沙,同時三氯沙牙膏則含有約0.3重量%的三氯沙。
用於本發明實務具有抗齲齒效力的焦磷酸鹽包括水溶性鹽類例如二鹼或四鹼金屬焦磷酸鹽如Na4P2O7(TSPP)、K4P2O7、NaK2P2O7、NaH2P2O7和K2H2P2O7。聚磷酸鹽包括水溶性鹼金屬三聚磷酸鹽例如三聚磷酸鈉和三聚磷酸鉀。
併入本發明潔齒劑組成物內的焦磷酸鹽濃度為約0.5至約2%重量比,以及較佳為約1.5至約2%重量比以及併入本發明潔齒劑組成物內的聚磷酸鹽濃度為約1至約7%重量比。
著色劑例如色素和染料可被用於本發明的實務。色素包括無毒性水溶性無機色素例如二氧化鈦和氧化鉻綠、群青藍和粉紅及氧化鐵以及藉由FD&C染料氧化鋁的擴充鈣或鋁鹽製造水不溶性染料色澱例如FD&C綠色1號色澱、FD&C藍色2號色澱、FD&C R&D#30色澱和FD&C #黃
色15色澱。該色素的粒度範圍為約5至約1000微米,較佳為約250至約500微米,以及濃度為約0.5至約3%重量比。
用於本發明實務的染料為食物和吞服藥物之食品、藥品和化妝品法核准的食物色素添加劑,包括染料例如FD&C紅色3號(四碘螢光黃的鈉鹽)、FD&C黃色5號(4-對磺基苯基偶氮-1-對磺酸苯基-5-羥基吡唑-3-甲酸的鈉鹽)、FD&C黃色6號(對磺基苯基偶氮-B-萘酚-6-單磺酸鹽的鈉鹽)、FD&C綠色3號(4-{[4-(N-乙基-對磺酸芐胺基)苯基]-(4-羥基-2-鋶苯基)亞甲基}-[1-(N-乙基-N-對磺酸芐基)-3,5-環己二烯亞胺]-的二鈉鹽)、FD&C藍色1號(二芐二乙基二胺三苯基甲醇-1-靛藍三磺酸的二鈉鹽),及其各種比例的混合物。可達到本發明最大效果的潔齒劑組成物內之染料濃度為從約0.0005至約2%的總重量。
利用本發明的雙組分潔齒劑具體實施例可獲得條式潔齒劑產品,其中各潔齒劑組分併入具有對比色的著色劑;該著色劑當使用建議劑量時為醫藥上和生理上無毒性。用於本發明實務的著色劑包括上述的色素和染料。
本發明潔齒劑組成物內可併入任何適合的調味劑或甜味劑。適當調味劑的實例為調味油例如留蘭香油、薄荷油、冬清油、黃樟油、丁香油、鼠尾草油、桉葉油、馬鬱蘭油、肉桂油、檸檬油和橙油,以及柳酸甲酯。適當甜味劑包括蔗糖、乳糖、麥芽糖、山梨糖、木糖、環拉酸鈉、紫蘇糖和糖精鈉。製劑內香料和甜味劑的總含量較佳為約0.01%至約5%或更高。
抗菌劑為酚和雙酚化合物、鹵化聯苯醚的非陽離子抗菌劑例如三氯沙、苯甲酸酯和羰醯胺苯,以及陽離子抗菌劑例如洗必泰(chlorhexidine digluconate)。此類抗菌劑的含量為從約0.03至約1%重量比的
特定組分。
當任何潔齒劑組分中含有非陽離子抗菌劑或抗菌劑時,較佳為亦含有從約0.05至約5%可加強該抗菌劑輸送和滯留於牙齒表面的物質。用於本發明的此類物質已揭示於美國專利案5,188,821和5,192,531;以及含有合成陰離子聚合聚羧酸鹽,例如馬來酸酐或酸與較佳為具有另一分子量(M.W.)約30,000至約1,000,000,最佳為約30,000至約800,000之可聚合乙烯化不飽和單體之較佳為甲基乙烯基醚/馬來酸酐的約1:4至約4:1共聚物。這些共聚物可供應自例如ISP技術公司Bound Brook市紐澤西州08805的Gantrez,如AN 139(分子量500,000)、AN 119(分子量250,000)以及較佳為醫藥級S-97(分子量700,000)。若存在這些加強劑時其含量為約0.05至約3%重量比。
為製備本發明的潔齒劑組分,通常將任何有機增稠劑、甜味劑、色素例如二氧化鈦及作為抗齲齒成分的任何聚磷酸鹽分散於濕潤劑例如丙二醇、聚乙二醇成分內。然後該分散物加入水與任何抗菌劑例如三氯沙、任何抗菌增強劑例如Gantrez和任何抗齲齒劑。在該第一中性pH組分內加入氟離子源去敏劑和磷酸鹽緩衝劑。在該第二組分內加入將pH調節至鹼性的成分,例如氫氧化鈉。混合這些成分直至各組分呈均質相時為止。然後加入無機增稠劑、矽磨料、香料和表面活性劑以及在從約20至約100毫米汞柱的真空下高速混合該成分。獲得的產物為各組分呈均質、半固體的可分配淤漿產品。
該潔齒劑組成物可藉由刷牙用牙膏或凝膠被施予於過敏牙齒表面,或利用軟性塗佈刷以液體光油直接局部塗抹於牙齒表面。
活性成分的濃度將視傳遞系統及特定作用的性質而定。
例如該鹼性胺基酸的濃度為從例如約0.1至約20重量%(以游
離鹼重量表示),例如潄口液為約0.1至約3重量%、消費性牙膏為約1至約10重量%或專業或處方治療產品為約7至約20重量%。氟化物的含量為從例如約25至約25,000ppm,例如潄口液為約25至約250ppm,消費性牙膏為約750至約2,000ppm,或專業或處方治療產品為約2,000至約25,000ppm。抗菌劑的濃度變化亦類似,用於牙膏的濃度為大於例如用於潄口液中的約5至約15倍。例如,三氯沙潄口液可含有例如約0.03重量%的三氯沙,同時三氯沙牙膏則含有約0.3重量%的三氯沙。
由於口腔組織係全身性感染的通道,因此加強口腔衛生亦有助於改善身體健康。良好口腔健康與身體包括心血管的健康有關。由於特別指精胺酸的鹼性胺基酸係供應NO合成徑路的氮源而加強口腔組織內的微循環,因此本發明的組成物及方法可提供特殊的效益。提供較低的酸性口腔環境亦有助於降低胃不適及產生不利於與胃潰瘍有關之螺旋桿菌的環境。精胺酸為高度表現特定免疫細胞受體例如T-細胞受體所必需,因而精胺酸可增強有效的免疫反應。本發明的組成物及方法因而可用於強化身體健康,包括心血管的健康。
本發明具體實施例的多組分潔齒劑組成物被包裝於適當的分配容器內,而該組分保持分開狀態並且該分開組分可如複合條帶被同步分配於牙刷。此類容器已為技術上所習知。此類容器的一實例為雙室分配容器,例如具有可壓縮側壁之述於美國專利案4,487,757和4,687,663的泵或管;其中該管體係由可壓縮塑膠網例如聚乙烯或聚丙烯所形成以及其具有容納各組分並且經由出口被分配之分隔室的體部。
由於口腔組織係全身性感染的通道,因此加強口腔衛生亦有助於改善身體健康。良好口腔健康與身體包括心血管的健康有關。由於特別指精胺酸的鹼性胺基酸係供應NO合成徑路的氮源而加強口腔組織內的
微循環,因此本發明的組成物及方法可提供特殊的效益。提供較低的酸性口腔環境亦有助於降低胃不適及產生不利於與胃潰瘍有關之螺旋桿菌的環境。精胺酸為高度表現特定免疫細胞受體例如T-細胞受體所必需,因而精胺酸可增強有效的免疫反應。本發明的組成物及方法因而可用於強化身體健康,包括心血管的健康。
全部使用期間,每一個值的扼要範圍描述均屬於本發明的範圍內。任何在該範圍內之值均可被選擇作為該範圍的界標。此外,藉由引述將全部引證於本發明揭示內的參考文獻完整併入於此。若本發明與所引述文獻的定義發生衝突時以本發明的揭示為準。很清楚地當描述配製物時可如同一般技術根據其成分進行描述,而儘管這些成分在實際製造、儲存和使用配製物時可能相互反應,但是此類產品亦仍屬於所述配製物的範圍。
利用下列實例進一步描述和證明本發明範圍內的舉例性具體實施例。該實例僅提供作為說明的用途以及由於其可作出許多不偏離本發明精神和範圍的改良而不得推論本發明僅侷限於該範圍。熟習本領域之技術者應瞭解本發明此處所示和說明者之外的各種改良而仍屬於附錄的申請專利範圍內。
製備本發明的雙組分(組分A和B)的去敏潔齒劑,將其指定為“潔齒劑X”組分A和組分B。當等量混合用於刷牙時,潔齒劑X將可有效加強抗齲齒和再礦化性質。組分A和B的成分列於下表I。
在製備潔齒劑X中,製備組分A和B其中在習知攪拌機內混
合甘油、聚乙二醇和有機增稠劑直至混合物成平滑外觀的淤漿為止。在加入水之前將顏料和甜味劑加入該淤漿內。然後將L-精胺酸混合入淤漿內及藉由加入磷酸進行中和。同時亦加入硝酸鉀。混合這些組分之後,將氧化矽、磷酸二鈣和山梨糖醇加入個別的組分然後混合均勻。最後將氟化物、月桂基硫酸鈉、香料和色素加入個別的潔齒劑組分接著在真空下再混合5~15分鐘以製備最終組分產品。
將兩種組分包裝入雙室管內以避免A內氟化物與B內鈣之間的反應。該雙室管容許雙相組分被分配成相貼附的條帶牙膏。
提供可溶性氟化鈉的氟化物以及具有高濃度的鈣、磷酸鹽和精胺酸可使這些成分在牙齒表面產生高可用濃度而因此有效減少脫礦化、促進再礦化及修補導致過敏而最終造成齲齒的琺瑯質損傷。
Claims (5)
- 一種組合物於製造用於消除或減少牙齒過敏相關之不適和疼痛的雙組分牙用組成物之用途,其中組合物包括第一組分,其含有會輕易地與磷酸鹽離子反應而沉澱CaPO4之鈣源或與氟化物反應而產生CaF2或氟化鈣-磷酸鹽混合物的鈣;含有陰離子源的第二組分,該陰離子源包含傳送25至25,000ppm氟離子濃度之氟離子源,以全部組成物重量為基準,磷酸鹽離子源,或其混合物;至少一組分含有精胺酸或其鹽,第一及第二組分彼此分開直到分配與合併,其中精胺酸以0.1至20%重量比之全部組成物存在,且第一組分與第二組分以等重量份存在;且其中第一和第二組分分開容納,分配和合併以及之後將該合併之組分施予至牙齒因而於存在鹼性胺基酸之下容許該陰離子與鈣離子反應產生鈣複合物沈澱物。
- 如申請專利範圍第1項之用途,其中各組分含有精胺酸。
- 如申請專利範圍第1項之用途,其中該氟離子源含有氟可釋鹽。
- 如申請專利範圍第1項之用途,其中該磷酸鹽離子源含有磷酸鹽可釋鹽。
- 如申請專利範圍第4項之用途,其中該磷酸鹽可釋鹽係磷酸鈉。
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2742208P | 2008-02-08 | 2008-02-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201442734A TW201442734A (zh) | 2014-11-16 |
| TWI552762B true TWI552762B (zh) | 2016-10-11 |
Family
ID=40952695
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW103121297A TWI552762B (zh) | 2008-02-08 | 2009-02-06 | 雙組分口腔保健產品 |
| TW098103784A TWI457141B (zh) | 2008-02-08 | 2009-02-06 | 雙組分口腔保健產品 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW098103784A TWI457141B (zh) | 2008-02-08 | 2009-02-06 | 雙組分口腔保健產品 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20110059029A1 (zh) |
| EP (1) | EP2249770A4 (zh) |
| JP (2) | JP5584629B2 (zh) |
| CN (2) | CN102764271B (zh) |
| AR (1) | AR070586A1 (zh) |
| AU (1) | AU2009212324B2 (zh) |
| BR (1) | BRPI0907102A2 (zh) |
| CA (1) | CA2710604C (zh) |
| CO (1) | CO6300924A2 (zh) |
| MX (1) | MX2010007740A (zh) |
| MY (1) | MY157315A (zh) |
| RU (1) | RU2476200C2 (zh) |
| TW (2) | TWI552762B (zh) |
| WO (1) | WO2009100268A2 (zh) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI446926B (zh) | 2010-01-29 | 2014-08-01 | Colgate Palmolive Co | 用於敏感性琺瑯質照護之口腔照護產品(一) |
| SG2014008742A (en) | 2011-09-08 | 2014-03-28 | Colgate Palmolive Co | Oral and skin care compositions based on a 3, 3 ' - dialkyl - 1, 1 ' - biphenyl - 2, 2 ' - diol or a 3, 3 ' -dialkenyl- 1, 1 ' -biphenyl- 2, 2 ' -diol |
| JP2013163656A (ja) * | 2012-02-10 | 2013-08-22 | Gc Corp | 歯磨剤 |
| RU2524614C1 (ru) * | 2013-08-01 | 2014-07-27 | Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Способ увеличения прочности цементов для медицины |
| JP6092751B2 (ja) * | 2013-10-25 | 2017-03-08 | ライオン株式会社 | 歯磨組成物 |
| CA2927611C (en) | 2013-12-03 | 2020-11-17 | Colgate-Palmolive Company | Oral care compositions |
| EP3193822A2 (en) * | 2014-09-15 | 2017-07-26 | Vizuri Health Sciences LLC | Polyphenol/flavonoid compositions and methods of formulating oral hygienic products |
| MX365972B (es) | 2014-12-23 | 2019-06-21 | Colgate Palmolive Co | Composiciones para el cuidado bucal. |
| AU2015369930B2 (en) * | 2014-12-23 | 2018-10-18 | Colgate-Palmolive Company | Oral care composition |
| JP6887948B2 (ja) * | 2014-12-29 | 2021-06-16 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 親油性薬剤を歯髄に送達するため、および象牙質生成を増強するための組成物および方法 |
| JP6523002B2 (ja) * | 2015-03-20 | 2019-05-29 | 東洋エアゾール工業株式会社 | 2液混合型エアゾール歯磨剤 |
| EP3288642B1 (en) * | 2015-04-29 | 2019-06-12 | Colgate-Palmolive Company | Oral care compositions |
| WO2017048617A1 (en) * | 2015-09-15 | 2017-03-23 | Vizuri Health Sciences Llc | Polyphenol/flavonoid compositions and methods of formulating oral hygienic products |
| CA3139976A1 (en) * | 2019-06-13 | 2020-12-17 | The Procter & Gamble Company | Kits comprising unit-dose oral care compositions |
| CN110693724B (zh) * | 2019-11-05 | 2020-10-30 | 浙江大学 | 一种牙齿矿化液及其矿化方法 |
| CN112336634B (zh) * | 2020-11-02 | 2022-03-22 | 浙江大学 | 基于微环境诱导纳米粒子再沉积的牙本质粘接预处理组合物及用途 |
| EP4014948A1 (de) * | 2020-12-18 | 2022-06-22 | Ivoclar Vivadent AG | Zusammensetzung zur remineralisation von zähnen |
| CN114939073A (zh) * | 2022-06-07 | 2022-08-26 | 云南白药集团健康产品有限公司 | 一种提高牙釉质再矿化效率的口腔护理用品及其制备方法与应用 |
| EP4292665A1 (en) * | 2022-06-16 | 2023-12-20 | Koninklijke Philips N.V. | An instantly formed cationic acp gel for treatment of tooth hypersensitivity |
| WO2023242172A1 (en) * | 2022-06-16 | 2023-12-21 | Koninklijke Philips N.V. | In situ formed cationic acp gel for treatment of tooth hypersensitivity |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5476647A (en) * | 1993-09-13 | 1995-12-19 | American Dental Association Health Foundation | Complex calcium and fluoride containing mouth rinses, dentifrices, and chewable tablets |
| GB2354441A (en) * | 1999-08-06 | 2001-03-28 | Mccormack Ltd | Composition for treating dentine hypersensitivity |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1352420A (en) * | 1971-06-18 | 1974-05-08 | Ajinomoto Kk | Arginine derivatives their production and their use |
| US3943241A (en) * | 1971-08-30 | 1976-03-09 | General Mills, Inc. | Cariostatic composition |
| US3932608A (en) * | 1971-08-30 | 1976-01-13 | General Mills, Inc. | Food composition |
| GB1408922A (en) * | 1972-02-02 | 1975-10-08 | Blendax Werke Schneider Co | Process and composition for the remineralisation and prevention of demineralisation of human teeth |
| US3932605A (en) * | 1972-06-12 | 1976-01-13 | Jaroslav Vit | Dental treatment |
| US3988434A (en) * | 1972-08-07 | 1976-10-26 | Schole Murray L | Dental preparation |
| US3863006A (en) * | 1973-01-29 | 1975-01-28 | Milton Hodosh | Method for desensitizing teeth |
| US4025616A (en) * | 1973-03-06 | 1977-05-24 | The Procter & Gamble Company | Oral compositions for plaque, caries and calculus retardation with reduced staining tendencies |
| US4100269A (en) * | 1973-06-28 | 1978-07-11 | Lever Brothers Company | Anticalculus dentifrice |
| US4022880A (en) * | 1973-09-26 | 1977-05-10 | Lever Brothers Company | Anticalculus composition |
| US3925543A (en) * | 1973-11-01 | 1975-12-09 | Colgate Palmolive Co | Antibacterial oral compositions containing preservative-antioxidants |
| US4011309A (en) * | 1975-01-20 | 1977-03-08 | Marion Laboratories, Inc. | Dentifrice composition and method for desensitizing sensitive teeth |
| US4064138A (en) * | 1975-11-12 | 1977-12-20 | General Mills, Inc. | Amino acid derivatives |
| ZA773318B (en) * | 1976-06-18 | 1978-04-26 | I Kleinberg | Means and method for improving natural defenses against caries |
| US4108981A (en) * | 1976-08-02 | 1978-08-22 | Indiana University Foundation | Alkaline oral compositions comprising aluminum and a carboxylic acid |
| US4108979A (en) * | 1976-08-02 | 1978-08-22 | Indiana University Foundation | Dentifrice preparations comprising aluminum and a compatible abrasive |
| US4042680A (en) * | 1976-08-02 | 1977-08-16 | Indiana University Foundation | Anticariogenic maloaluminate complexes |
| US4146607A (en) * | 1977-11-07 | 1979-03-27 | Lever Brothers Company | Synergistic anti-plaque mixture with tetradecylamine plus aluminum and/or zinc |
| US4160821A (en) * | 1978-02-27 | 1979-07-10 | Johnson & Johnson | Treatment for gingivitis |
| GB1573727A (en) * | 1978-05-19 | 1980-08-28 | Colgate Palmolive Co | Dentifrices |
| US4216961A (en) * | 1978-08-04 | 1980-08-12 | Mcquillan Mary J | Table baseball apparatus |
| US4225579A (en) * | 1979-02-27 | 1980-09-30 | Israel Kleinberg | Means and method for improving defenses against caries |
| US4339432A (en) * | 1979-06-20 | 1982-07-13 | Lever Brothers Company | Oral mouthwash containing zinc and glycine |
| US4269822A (en) * | 1979-07-20 | 1981-05-26 | Laclede Professional Products, Inc. | Antiseptic dentifrice |
| JPS5835965B2 (ja) * | 1979-07-31 | 1983-08-05 | ライオン株式会社 | 口腔用組成物 |
| JPS5846483B2 (ja) * | 1979-09-20 | 1983-10-17 | ライオン株式会社 | 口腔用組成物 |
| US4532124A (en) * | 1981-08-19 | 1985-07-30 | Development Finance Corporation Of New Zealand | Dental rinse |
| US4487757A (en) * | 1981-12-28 | 1984-12-11 | Colgate-Palmolive Company | Dispensing container of toothpaste which effervesces during toothbrushing |
| JPS58118509A (ja) * | 1981-12-29 | 1983-07-14 | Lion Corp | 口腔用組成物 |
| US4499067A (en) | 1982-08-26 | 1985-02-12 | Johnson & Johnson Products, Inc. | Oral compositions comprising NG -acyl derivatives of arginine |
| US4687663B1 (en) * | 1983-03-01 | 1997-10-07 | Chesebrough Ponds Usa Co | Dental preparation article and method for storage and delivery thereof |
| US4725576A (en) * | 1983-12-29 | 1988-02-16 | Research Foundation Of State University Of New York | Fungicidal polypeptide compositions containing L-histidine and methods for use therefore |
| US4528181A (en) * | 1984-02-01 | 1985-07-09 | Colgate-Palmolive Company | Dentifrice containing dual sources of fluoride |
| US5334617A (en) * | 1984-03-19 | 1994-08-02 | The Rockefeller University | Amino acids useful as inhibitors of the advanced glycosylation of proteins |
| GB8411731D0 (en) * | 1984-05-09 | 1984-06-13 | Unilever Plc | Oral compositions |
| JPH0742219B2 (ja) * | 1984-07-26 | 1995-05-10 | ライオン株式会社 | 口腔用組成物 |
| US4538990A (en) * | 1984-09-24 | 1985-09-03 | Medical College Of Ga. Research Institute, Inc. | Method of decreasing the permeability of a dental cavity |
| US5188821A (en) * | 1987-01-30 | 1993-02-23 | Colgate-Palmolive Company | Antibacterial antiplaque oral composition mouthwash or liquid dentifrice |
| US5192531A (en) * | 1988-12-29 | 1993-03-09 | Colgate-Palmolive Company | Antibacterial antiplaque oral composition |
| GB8729564D0 (en) * | 1987-12-18 | 1988-02-03 | Unilever Plc | Oral compositions |
| US5096700A (en) * | 1990-09-28 | 1992-03-17 | The Procter & Gamble Company | Halogenated aminohexanoates and aminobutyrates antimicrobial agents |
| US5286480A (en) * | 1992-06-29 | 1994-02-15 | The Procter & Gamble Company | Use of N-acetylated amino acid complexes in oral care compositions |
| ES2125485T3 (es) * | 1993-09-13 | 1999-03-01 | American Dental Ass | Colutorios, dentrificos y tabletas de mascar conteniendo calcio complejo y fluoruro. |
| CA2209556A1 (en) * | 1995-01-06 | 1996-07-11 | American Dental Association Health Foundation | Control of calcium fluoride formation in mouth rinses, dentifrices and gels |
| US5605675A (en) * | 1995-06-06 | 1997-02-25 | Enamelon Inc. | Processes and compositions for remineralization and prevention of demineralization of dental enamel |
| US5762911A (en) * | 1996-03-05 | 1998-06-09 | The Research Foundation Of State University Of New York | Anti-caries oral compositions |
| US5785956A (en) * | 1996-06-07 | 1998-07-28 | Colgate Palmolive Company | Dual component dentifrice composition for dental fluoridation |
| UA51721C2 (uk) * | 1996-09-12 | 2002-12-16 | Смітклайн Бічем Консьюмер Хелскеа Гмбх | Ремінералізуюча композиція |
| US6303104B1 (en) * | 1999-02-12 | 2001-10-16 | Enamelon, Inc. | Remineralizing/mineralizing oral products having improved whitening and stain removal properties |
| US6436370B1 (en) * | 1999-06-23 | 2002-08-20 | The Research Foundation Of State University Of New York | Dental anti-hypersensitivity composition and method |
| BR0313249B1 (pt) * | 2002-08-05 | 2014-04-22 | Colgate Palmolive Co | Composição dentária para eliminar ou reduzir o desconforto e a dor associados com a hipersensibilidade dentinária |
| JP2006069990A (ja) * | 2004-09-03 | 2006-03-16 | Kao Corp | 口腔用組成物 |
| CA2587077C (en) * | 2004-11-09 | 2014-03-25 | Discus Dental Impressions, Inc. | Dental whitening systems |
-
2009
- 2009-02-06 CA CA2710604A patent/CA2710604C/en not_active Expired - Fee Related
- 2009-02-06 AU AU2009212324A patent/AU2009212324B2/en not_active Ceased
- 2009-02-06 TW TW103121297A patent/TWI552762B/zh not_active IP Right Cessation
- 2009-02-06 BR BRPI0907102A patent/BRPI0907102A2/pt active Search and Examination
- 2009-02-06 RU RU2010137324/15A patent/RU2476200C2/ru not_active IP Right Cessation
- 2009-02-06 US US12/866,639 patent/US20110059029A1/en not_active Abandoned
- 2009-02-06 TW TW098103784A patent/TWI457141B/zh not_active IP Right Cessation
- 2009-02-06 MX MX2010007740A patent/MX2010007740A/es unknown
- 2009-02-06 AR ARP090100432A patent/AR070586A1/es unknown
- 2009-02-06 MY MYPI2010002607A patent/MY157315A/en unknown
- 2009-02-06 WO PCT/US2009/033295 patent/WO2009100268A2/en not_active Ceased
- 2009-02-06 CN CN201210249396.4A patent/CN102764271B/zh not_active Expired - Fee Related
- 2009-02-06 JP JP2010546019A patent/JP5584629B2/ja not_active Expired - Fee Related
- 2009-02-06 CN CN2009801046404A patent/CN101938975B/zh not_active Expired - Fee Related
- 2009-02-06 EP EP20090707335 patent/EP2249770A4/en not_active Ceased
-
2010
- 2010-09-02 CO CO10108727A patent/CO6300924A2/es not_active Application Discontinuation
-
2014
- 2014-07-18 JP JP2014147534A patent/JP2014221814A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5476647A (en) * | 1993-09-13 | 1995-12-19 | American Dental Association Health Foundation | Complex calcium and fluoride containing mouth rinses, dentifrices, and chewable tablets |
| GB2354441A (en) * | 1999-08-06 | 2001-03-28 | Mccormack Ltd | Composition for treating dentine hypersensitivity |
Also Published As
| Publication number | Publication date |
|---|---|
| US20110059029A1 (en) | 2011-03-10 |
| EP2249770A4 (en) | 2014-02-19 |
| CA2710604A1 (en) | 2009-08-13 |
| TW201442734A (zh) | 2014-11-16 |
| TWI457141B (zh) | 2014-10-21 |
| JP2011511795A (ja) | 2011-04-14 |
| JP2014221814A (ja) | 2014-11-27 |
| AU2009212324B2 (en) | 2011-12-08 |
| MY157315A (en) | 2016-05-31 |
| CN102764271A (zh) | 2012-11-07 |
| TW200948385A (en) | 2009-12-01 |
| RU2476200C2 (ru) | 2013-02-27 |
| BRPI0907102A2 (pt) | 2016-05-03 |
| CN101938975B (zh) | 2012-09-05 |
| JP5584629B2 (ja) | 2014-09-03 |
| EP2249770A2 (en) | 2010-11-17 |
| CO6300924A2 (es) | 2011-07-21 |
| CA2710604C (en) | 2014-07-08 |
| MX2010007740A (es) | 2010-08-06 |
| WO2009100268A2 (en) | 2009-08-13 |
| AU2009212324A1 (en) | 2009-08-13 |
| CN101938975A (zh) | 2011-01-05 |
| RU2010137324A (ru) | 2012-03-20 |
| WO2009100268A3 (en) | 2009-11-05 |
| AR070586A1 (es) | 2010-04-21 |
| CN102764271B (zh) | 2016-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI552762B (zh) | 雙組分口腔保健產品 | |
| CN101938982B (zh) | 口腔护理产品和其使用和制备方法 | |
| TWI507211B (zh) | 含四鹼基鋅-胺基酸鹵化物錯合物及半胱胺酸之二成分組成物 | |
| US6696047B2 (en) | Stable oral care compositions comprising chlorite | |
| US6350438B1 (en) | Oral care compositions comprising chlorite and methods | |
| AU2009212320B2 (en) | Oral care product and methods of use thereof | |
| CN100536812C (zh) | 牙本质脱敏牙膏 | |
| CN103153267B (zh) | 口腔护理产品及其使用和制备方法 | |
| TWI499430B (zh) | 抗侵蝕的牙膏組成物 | |
| JP2011511065A (ja) | アルギニン塩および口腔における疾患を処置するためのそれらの使用 | |
| AU762031B2 (en) | Dual component dentinal desensitizing dentifrice | |
| JP2015221814A (ja) | オーラルケア製品およびその使用法および製造法 | |
| MXPA05001377A (es) | Dentifrico desensibilizante dental que proporciona beneficios de remineralizacion y anticaries mejorados. | |
| MXPA01007327A (en) | Dual component dentinal desensitizing dentifrice | |
| HK1088546B (zh) | 穩定的包含亞氯酸鹽的口腔護理組合物 | |
| MXPA00010014A (en) | Desensitizing dentifrice containing potassium and tin salts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |